Allergy Therapeutics Plc (AGY):企業の財務・戦略的SWOT分析

【英語タイトル】Allergy Therapeutics Plc (AGY) - Financial and Strategic SWOT Analysis Review

GlobalDataが出版した調査資料(DATA904C9451)・商品コード:DATA904C9451
・発行会社(調査会社):GlobalData
・発行日:2018年11月
・ページ数:59
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Allergy Therapeutics Plc (AGY) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Allergy Therapeutics Plc (Allergy Therapeutics) is a specialty pharmaceutical company that develops therapies for allergy treatment and allergy prevention. The company offers a wide range of aluminium-free allergy vaccines and diagnostics. It uses Micro Crystalline Tyrosine (MCT) as an alternative of aluminium to develop aluminium-free immunotherapy vaccines. Allergy Therapeutics product portfolio includes Pollinex Grasses + Rye and Pollinex Trees vaccines. It also offers allergen extracts used for skin prick testing. The company’s diagnostics products comprise of Pollen, Moulds, Arthropods, Epithelia and others. It has operational presence in Germany, Italy, Spain, Austria, Switzerland, Slovakia, Czech Republic, the Netherlands and the UK. Allergy Therapeutics is headquartered in Worthing, West Sussex, the UK.

Allergy Therapeutics Plc Key Recent Developments

Sep 26,2018: Allergy Therapeutics announces preliminary results for the year ended 30 June 2018
Jul 12,2018: Allergy Therapeutics: Trading Update
May 14,2018: Allergy Therapeutics Publishes New Data Validating Mode of Action and Unique Adjuvant Properties of its Patented Adjuvant, Microcrystalline Tyrosine (MCT®), in The Journal of Immunology
Mar 07,2018: Allergy Therapeutics: Interim Results for the six months ended 31 December 2017
Feb 02,2018: Allergy Therapeutics Announces Corporate Update

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1 – About the Company 6
Allergy Therapeutics Plc – Key Facts 6
Allergy Therapeutics Plc – Key Employees 7
Allergy Therapeutics Plc – Key Employee Biographies 8
Allergy Therapeutics Plc – Key Operational Employees 9
Allergy Therapeutics Plc – Major Products and Services 10
Allergy Therapeutics Plc – History 11
Allergy Therapeutics Plc – Company Statement 13
Allergy Therapeutics Plc – Locations And Subsidiaries 14
Head Office 14
Other Locations & Subsidiaries 14
Section 2 – Company Analysis 16
Company Overview 16
Allergy Therapeutics Plc – Business Description 17
Allergy Therapeutics Plc – Corporate Strategy 18
Allergy Therapeutics Plc – SWOT Analysis 19
SWOT Analysis – Overview 19
Allergy Therapeutics Plc – Strengths 19
Allergy Therapeutics Plc – Weaknesses 20
Allergy Therapeutics Plc – Opportunities 21
Allergy Therapeutics Plc – Threats 22
Allergy Therapeutics Plc – Key Competitors 23
Section 3 – Company Financial Ratios 24
Financial Ratios – Capital Market Ratios 24
Financial Ratios – Annual Ratios 25
Performance Chart 28
Financial Performance 28
Financial Ratios – Interim Ratios 29
Financial Ratios – Ratio Charts 30
Section 4 – Company’s Lifesciences Financial Deals and Alliances 31
Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 31
Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 32
Allergy Therapeutics Plc, Recent Deals Summary 33
Section 5 – Company’s Recent Developments 34
Sep 26, 2018: Allergy Therapeutics announces preliminary results for the year ended 30 June 2018 34
Jul 12, 2018: Allergy Therapeutics: Trading Update 39
May 14, 2018: Allergy Therapeutics Publishes New Data Validating Mode of Action and Unique Adjuvant Properties of its Patented Adjuvant, Microcrystalline Tyrosine (MCT®), in The Journal of Immunology 40
Mar 07, 2018: Allergy Therapeutics: Interim Results for the six months ended 31 December 2017 41
Feb 02, 2018: Allergy Therapeutics Announces Corporate Update 44
Jan 31, 2018: Allergy Therapeutics: Trading Update 46
Sep 28, 2017: Allergy Therapeutics: Preliminary Results 47
Sep 11, 2017: Allergy Therapeutics: Expansion of Clinical Development and R&D teams 52
Jun 06, 2017: Allergy Therapeutics: Directorate changes 53
Mar 29, 2017: Allergy Therapeutics: Interim Results for the six months ended 31 December 2016 54
Section 6 – Appendix 55
Methodology 55
Ratio Definitions 55
About GlobalData 59
Contact Us 59
Disclaimer 59

List of Tables
Allergy Therapeutics Plc, Key Facts 6
Allergy Therapeutics Plc, Key Employees 7
Allergy Therapeutics Plc, Key Employee Biographies 8
Allergy Therapeutics Plc, Key Operational Employees 9
Allergy Therapeutics Plc, Major Products and Services 10
Allergy Therapeutics Plc, History 11
Allergy Therapeutics Plc, Subsidiaries 14
Allergy Therapeutics Plc, Key Competitors 23
Allergy Therapeutics Plc, Ratios based on current share price 24
Allergy Therapeutics Plc, Annual Ratios 25
Allergy Therapeutics Plc, Annual Ratios (Cont...1) 26
Allergy Therapeutics Plc, Annual Ratios (Cont...2) 27
Allergy Therapeutics Plc, Interim Ratios 29
Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 31
Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 32
Allergy Therapeutics Plc, Recent Deals Summary 33
Currency Codes 55
Capital Market Ratios 55
Equity Ratios 56
Profitability Ratios 56
Cost Ratios 57
Liquidity Ratios 57
Leverage Ratios 58
Efficiency Ratios 58

List of Figures
Allergy Therapeutics Plc, Performance Chart (2014 - 2018) 28
Allergy Therapeutics Plc, Ratio Charts 30
Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 31
Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 32

★調査レポート[Allergy Therapeutics Plc (AGY):企業の財務・戦略的SWOT分析] (コード:DATA904C9451)販売に関する免責事項を必ずご確認ください。
★調査レポート[Allergy Therapeutics Plc (AGY):企業の財務・戦略的SWOT分析]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆